The significance of Ki-67 proliferative index and cyclin D1 expression of dysplastic nevi in the biologic spectrum of melanocytic lesions

Applied Immunohistochemistry and Molecular Morphology

Volumn 15, Issue 2, 2007, Pages 160-164

  Lebe, Banu ^a   Pabuççuoǧlu, Uǧur ^a   Özer, Erdener ^a  

^a DOKUZ EYLUL UNIVERSITY   (Turkey)

Author keywords

Common melanocytic nevi; Cyclin D1; Dysplastic nevi; Ki 67 index; Melanoma

Indexed keywords

ANTIBODY; BIOLOGICAL MARKER; CYCLIN D1; KI 67 ANTIGEN;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER SUSCEPTIBILITY; CHILD; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE COURSE; DYSPLASTIC NEVUS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MELANOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; TISSUE SECTION;

CYCLIN D1; DYSPLASTIC NEVUS SYNDROME; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MELANOMA; NEVUS, PIGMENTED; TUMOR MARKERS, BIOLOGICAL;

EID: 34249738595     PISSN: 15412016     EISSN: 15334058     Source Type: Journal    
DOI: 10.1097/01.pai.0000209868.58699.64     Document Type: Article

References (35)

1. Skender-Kalnesas TM, English DR, Heenan PJ. Benign melanocytic lesions: risk markers or precursors of cutaneous melanoma? J Am Acad Dermatol. 1995;33:1000-1007.
2. Elder DE, Goldman LI, Goldman SC, et al. Dysplastic nevus syndrome: a phenotypic association of sporadic cutaneous melanoma. Cancer. 1980;46:1787-1794.
3. Barnhill RL, Roush GC, Duray PH. Correlation of histologic architectural and cytoplasmic features with nuclear atypia in atypical (dysplastic) nevomelanocytic nevi. Hum Pathol. 1990;21:51-58.
4. Blessing K. Benign atypical naevi: diagnostic difficulties and continued controversy. Histopathology. 1999;34:189-198.
5. Grene MH. The genetics of hereditary melanoma and nevi. Cancer. 1999;86:2464-2477.
6. Bauer J, Garbe C. Acquired melanocytic nevi as risk factor for melanoma development. A comprehensive review of epidemiological data. Pigment Cell Res. 2003;16:297-306.
7. Lew DJ, Dulic V, Reed SI. Isolation of three novel human cyclins by rescue of G1 cyclin function in yeast. Cell. 1991;66:1197-1206.
8. Hunter T, Pines J. Cyclins and cancer II: cyclin D and CDK inhibitors comes of age. Cell. 1994;79:573-582.
9. Sherr CJ. Cancer cell cycles. Science. 1996;274:1672-1677.
10. Xiong Y, Connolly T, Futcher B, et al. Human D-type cyclin. Cell. 1991;65:691-699.
11. Keyomarsi K, Pardee AB. Redundant cyclin overexpression and gene amplification in breast cancer cell. Proc Natl Acad Sci USA. 1993;90:1112-1116.
12. Akervall JA, Michalides RJ, Mineta H, et al. Amplification of cyclin D1 in squamous cell carcinoma of the head and neck and the prognostic value of chromosomal abnormalities and cyclin D1 overexpression. Cancer. 1997;79:380-389.
13. Jiang W, Kahn SM, Tomita N, et al. Amplification and expression of the human cyclin D gene in esophageal cancer. Cancer Res. 1992;52:2980-2983.
14. Arber N, Gammon MD, Hibshoosh H, et al. Overexpression of cyclin D1 occurs in both squamous carcinomas and adenocarcinomas of the esophagus and in adenocarcinomas of the stomach. Hum Pathol. 1999;30:1087-1092.
15. Madea K, Chung YS, Kang SM, et al. Cyclin D1 overexpression and prognosis in colorectal adenocarcinoma. Oncology. 1998;55:145-151.
16. Zhang YJ, Jiang W, Chen CJ, et al. Amplification and overexpression of cyclin D1 in human hepatocellular carcinoma. Biochem Biophys Res Commun. 1993;196:1010-1016.
17. Brynes RK, McCourty A, Tamayo R, et al. Demonstration of cyclin D1 (bcl-1) in mantle cell lymphoma: enhanced staining using heat and ultrasound epitope retrieval. Appl Immunohistochem. 1997;5:45-48.
18. Linden MD, Torres FX, Kubus J, et al. Clinical application of morphologic and immunocytochemical assessments of cell proliferation. Am J Clin Pathol. 1992;97:4-13.
19. Gerdes J, Lemke H, Baisch H, et al. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol. 1984;133:1710-1715.
20. Rieger E, Hofmann-Wellenhof R, Soyer HP, et al. Comparison of proliferative activity as assessed by proliferating cell nuclear antigen (PCNA) and Ki-67 monoclonal antibodies in melanocytic skin lesions. A quantitative immunohistochemical study. J Cutan Pathol. 1993;20:229-236.
21. Greene FL, Page DL, Fleming ID, et al. Melanoma of the Skin. In: AJCC Cancer Staging Manual. 6th ed. New York: Springer; 2002:209-220.
22. Clemente C, Cochran AJ, Elder DE, et al. Histopathologic diagnosis of dysplastic nevi: concordance among pathologists convened by the World Health Organization melanoma Programme. Hum Pathol. 1991;22:313-319.
23. Georgieva J, Sinha P, Schadendorf D. Expression of cyclins and cyclin dependent kinases in human benign and malignant melanocytic lesions. J Clin Pathol. 2001;54:229-235.
24. Nagasaka T, Lai R, Medeiros LJ, et al. Cyclin D1 overexpression in Spitz Nevi: an immunohistochemical study. Am J Dermatopathol. 1999;21:115-120.
25. Lebe B, Saǧol O, Ulukuş Ç, et al. The importance of cyclin D1 and Ki-67 expression on the biological behavior of pancreatic adenocarcinomas. Pathol Res Pract. 2004;200:389-396.
26. Ben-Izhak O, Bar-Chara M, Susman L, et al. Ki67 antigen and PCNA proliferative markers predict survival in anorectal malignant melanoma. Histopathology. 2002;41:519-525.
27. Li LL, Crotty KA, McCarthy SW, et al. A zonal comparison of MIB1-Ki67 immunoreactivity in benign and malignant lesions. Am J Dermatopathol. 2000;22:489-495.
28. Moretti S, Massobrio R, Brogelli L, et al. Ki67 antigen expression correlates with tumor progression and HLA-DR antigen expression in melanocytic lesions. J Invest Dermatol. 1990;95:320-324.
29. Moretti S, Spallanzani A, Chiarugi A, et al. Correlation of Ki-67 expression in cutaneous primary melanoma with prognosis in a prospective study: different correlation according to thickness. J Am Acad Dermatol. 2001;44:188-192.
30. Sparrow LE, Taran JM, Heenan PJ. Prognostic significance of MIB-1 proliferative activity in thin melanomas and immunohistochemical analysis of MIB-1 proliferative activity in melanocytic tumors. Am J Dermatopathol. 1998;20:12-16.
31. Sauter ER, Yeo UC, vonStemm A, et al. Cyclin D1 is a candidate oncogene in cutaneous melanoma. Cancer Res. 2002;62:3200-3206.
32. Ewanowich C, Brynes RK, Medeiros LJ, et al. Cyclin D1 expression in dysplastic nevi. Arch Pathol Lab Med. 2001;125:208-210.
33. Alonso SR, Ortiz P, Pollan M, et al. Progression in cutaneous malignant melanoma is associated with distinct expression profiles. Am J Pathol. 2004;164:193-203.
34. Florenes VA, Faye RS, Maelandsmo GM, et al. Levels of cyclin D1 and cyclin D3 expression is associated with poor clinical outcome in superficial melanoma. Clin Cancer Res. 2000;6:3614-3620.
35. Ramirez JA, Guitart J, Rao S, et al. Cyclin D1 expression in melanocytic lesions of the skin. Ann Diagn Pathol. 2005;9:185-188.